Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on July 22, 2010. The report addresses two critical events: a hearing regarding a breach of contract lawsuit against SIGA Technologies and a notification from the NYSE Amex LLC concerning non-compliance with continued listing standards.
Key Financial Metrics and Liquidity
- Stockholders' Equity: The filing states the company has stockholders' equity of less than $2.0 million, $4.0 million, and $6.0 million, failing to meet specific thresholds for the last two, three, and five fiscal years respectively.
- Net Losses: The company reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, three of its four most recent fiscal years, and its five most recent fiscal years.
- Market Capitalization: As of July 22, 2010, with a closing share price of $1.51 and including 2,785,714 shares from a registered direct offering, the market capitalization was approximately $49.54 million. This figure includes 37,100 fully vested options and warrants with an exercise price of $1.51 or less.
- Revenue and Cash Flow: The filing text does not provide specific values for revenue, operating cash flow, or debt levels.
Material Changes and Events
- Litigation Update: The Delaware Court of Chancery held a hearing on SIGA Technologies' motion for partial summary judgment. The court indicated a desire to schedule a trial no later than early January 2011 but reserved its decision on the motion.
- Listing Compliance: The NYSE Amex LLC notified the company of non-compliance with Section 1003(a) of the Company Guide due to insufficient stockholders' equity and recurring net losses.
Outlook, Risks, and Contingencies
- Delisting Risk: The company must submit a plan to regain compliance within 30 days of receiving the formal letter. If the plan is accepted, the company has up to 18 months to comply. Failure to submit or have the plan accepted may lead to delisting proceedings.
- Market Cap Threshold: The Exchange noted that suspension or removal is not normally considered if the issuer sustains a total market capitalization of at least $50 million. The company's calculated market cap of $49.54 million falls just short of this threshold.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks related to product development, future financial conditions, and collaboration agreements.
Investor Verification Checklist
- Verify the exact date of receipt of the formal non-compliance letter from NYSE Amex to determine the 30-day deadline for the compliance plan.
- Confirm the final status of the SIGA Technologies lawsuit and the scheduled trial date in early 2011.
- Monitor the company's ability to raise capital or restructure to meet the $50 million market capitalization threshold or equity requirements.
- Review the details of the registered direct offering mentioned to understand the dilution impact and capital raised.